Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
01
2021
accepted:
07
06
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
17
11
2021
Statut:
epublish
Résumé
We assessed the applicability of next-generation sequencing (NGS)-based IGH/IGK clonality testing and analyzed the repertoire of immunoglobulin heavy chain (IGH) or immunoglobulin kappa light chain (IGK) gene usage in Korean patients with multiple myeloma (MM) for the first time. Fifty-nine bone marrow samples from 57 Korean patients with MM were analyzed, and NGS-based clonality testing that targeted the IGH and IGK genes was performed using IGH FR1 and IGK primer sets. Clonal IGH and IGK rearrangements were observed in 74.2% and 67.7% of samples from Korean patients with kappa-restricted MM, respectively (90.3% had one or both), and in 60.7% and 95.5% of samples from those with lambda-restricted MM, respectively (85.7% had one or both). In total, 88.1% of samples from Koreans with MM had clonal IGH and/or IGK rearrangement. Clonal rearrangement was not significantly associated with the bone marrow plasma cells as a proportion of all BM lymphoid cells. IGHV3-9 (11.63%) and IGHV4-31 (9.30%) were the most frequently reported IGHV genes and were more common in Koreans with MM than in Western counterparts. IGHD3-10 and IGHD3-3 (13.95% each) were the most frequent IGHD genes; IGHD3-3 was more common in Koreans with MM. No IGK rearrangement was particularly prevalent, but single IGKV-J rearrangements were less common in Koreans with kappa-restricted MM than in Western counterparts. IGKV4-1 was less frequent in Koreans regardless of light chain type. Otherwise, the usages of the IGH V, D, and J genes and of the IGK gene were like those observed in previous Western studies. NGS-based IGH/IGK clonality testing ought to be applicable to most Koreans with MM. The overrepresentation of IGHV3-9, IGHV4-31, and IGHD3-3 along with the underrepresentation of IGKV4-1 and the differences in IGK gene rearrangement types suggest the existence of ethnicity-specific variations in this disease.
Identifiants
pubmed: 34166440
doi: 10.1371/journal.pone.0253541
pii: PONE-D-21-02727
pmc: PMC8224885
doi:
Substances chimiques
Immunoglobulin Heavy Chains
0
Immunoglobulin kappa-Chains
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0253541Déclaration de conflit d'intérêts
No authors have competing interests.
Références
J Clin Oncol. 2011 Apr 20;29(12):1627-33
pubmed: 21402611
Leukemia. 2012 Oct;26(10):2159-71
pubmed: 22918122
Int J Hematol. 2010 Jul;92(1):52-7
pubmed: 20544403
J Mol Diagn. 2000 Nov;2(4):178-90
pubmed: 11232108
Haematologica. 2012 Jun;97(6):849-53
pubmed: 22207685
Blood. 2015 Aug 20;126(8):1045-7
pubmed: 26294720
Blood Cancer J. 2020 Feb 6;10(2):14
pubmed: 32029700
J Mol Diagn. 2019 Mar;21(2):330-342
pubmed: 30590126
J Immunol. 2005 Nov 1;175(9):5912-22
pubmed: 16237084
Ther Adv Hematol. 2014 Apr;5(2):35-47
pubmed: 24688753
J Exp Med. 2005 Jun 6;201(11):1715-23
pubmed: 15928199
J Immunol. 2017 May 15;198(10):3765-3774
pubmed: 28416603
Blood. 1996 Apr 1;87(7):2846-52
pubmed: 8639903
Blood. 2004 Aug 1;104(3):607-18
pubmed: 15090448
Haematologica. 2005 Jul;90(7):906-13
pubmed: 15996928
Leukemia. 2007 Feb;21(2):207-14
pubmed: 17170731
Leukemia. 2019 Sep;33(9):2227-2240
pubmed: 31197258
Korean J Intern Med. 2016 Sep;31(5):820-34
pubmed: 27604794
Blood. 2007 Nov 1;110(9):3112-21
pubmed: 17634408
PLoS One. 2019 Mar 22;14(3):e0211600
pubmed: 30901326
J Clin Oncol. 2013 Jul 10;31(20):2523-6
pubmed: 23733782
Cancer Res Treat. 2015 Apr;47(2):127-41
pubmed: 25761484
J Immunol. 1995 Sep 1;155(5):2487-97
pubmed: 7650379
Haematologica. 2006 Jun;91(6):781-7
pubmed: 16769580
N Engl J Med. 2002 Feb 21;346(8):564-9
pubmed: 11856795
Br J Haematol. 1994 May;87(1):68-74
pubmed: 7947257
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Br J Haematol. 2007 Jul;138(1):31-43
pubmed: 17555445
Sci Transl Med. 2009 Dec 23;1(12):12ra23
pubmed: 20161664
Acta Haematol. 2009;122(4):200-10
pubmed: 19887776
Front Oncol. 2019 Aug 20;9:699
pubmed: 31482061